EBS Emergent BioSolutions: Year-over-year earnings per share growth for the last twelve months

EBS (Emergent BioSolutions Inc.) - company brandmark

Historical quarterly EPS growth demonstrates the impact of exclusive government contracts for biodefense and opioid combat, with the metric settling at -171.00. Emergent BioSolutions (EBS) relies on expanding retail drug sales to reduce its dependence on government orders. However, the post-pandemic slowdown in flows and the necessity of cost reductions are creating certain inertia in the company's operational activities.

Emergent BioSolutions Inc. (EBS) - Earnings per share growth in annualized terms for the last twelve months from 07/04/2022 to 11/11/2026

Analytical breakdowns for Emergent BioSolutions

- share price and consensus valuation forecast:
Stock Quotes Emergent BioSolutions Inc.|EBS - Analyst Consensus Forecast
- company stock capitalization data:
Market Value Emergent Corp|EBS - Company Buyout Price
- book capitalization data:
Book Value per Share Emergent BioSolutions|EBS - Total Stockholders' Equity|Market Value to Book Value Ratio emergentbiosolutions.com|EBS - Cumulative Company Assets
- debt level and financial liquidity data:
Total Debt to Capital Emergent BioSolutions|EBS - Long-Term Liabilities to Capital|Short-Term Debt to Equity Emergent BioSolutions|EBS - Aggregate Debt Obligations|Debts to Book Capitalization Emergent Corp|EBS - Long-Term Indebtedness|Company Short-Term Debts Emergent BioSolutions|Quick Liquidity emergentbiosolutions.com
- earnings and valuation multiples indicators:
EBS - Company Profit|Future Profit Emergent BioSolutions|EBS - Market Price to Net Income Ratio|Projected Price to Earnings Emergent Corp|EBS - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Emergent Corp|EBS - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Emergent BioSolutions|EBS - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months emergentbiosolutions.com|EBS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Emergent BioSolutions
Summary company analytics:Emergent BioSolutions Inc. - EBS
Flagship merchandise of Emergent BioSolutions

The development of innovative vaccines and biodefense systems by Emergent BioSolutions (EBS) requires colossal R&D expenditures. Quarterly earnings growth (EPS) measures the percentage change in net income per share relative to the previous period. By analyzing this quarterly EPS growth chart, an investor assesses the efficiency of monetizing scientific achievements. Positive momentum confirms the company's ability to transform technologies into actual revenue. The stability of this metric determines the issuer's fair market value.

Competitors of Emergent BioSolutions

GILD (Gilead Sciences) - Year-over-year net earnings per share growth for the last 12 months|Cidara Corp (CDTX) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Novavax Corp|CureVac Pharma (CVAC) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth VALN|VIR - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months SIGA Technologies SIGA|AVIR - Year-over-year net earnings per share growth for the last 12 months|Invivyd Corp - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Enanta Pharmaceuticals, Inc|Inovio Pharmaceuticals (INO) - Year-over-year earnings per share growth for the last twelve months|hillevax.com - Year-over-year earnings per one share growth for the last 12 months|KLRS (Kalaris Therapeutics) - Quarterly EPS earnings growth|DYAI - Net earnings per share growth for the trailing year|Quarterly EPS earnings growth NNVC|TLPH - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma, Inc. COCP|TRAW: Year-over-year earnings per share growth for the last 12 months|DWTX: Year-over-year net earnings per share growth for the last 12 months|Qualigen Therapeutics Inc - Year-over-year earnings per share growth rate for the last twelve months|ALVR (allovir.com) - Year-over-year net earnings per share growth for the last 12 months|VBI Vaccines - Year-over-year earnings per one share growth for the last 12 months|VIRI (Virios Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months VXRT